RESUMO
BACKGROUND: Regarding the pathophysiology of renal infarction (RI), cardioembolic causes could have large proportion. However, there are notable variations in prevalence of atrial fibrillation (AF) among patients with RI across different studies, ranging from 17 to 65%. The primary objective of this study is to analyze the incidence of AF in patients with RI. METHODS: This nationwide retrospective cohort study enrolled 5200 patients with RI from the Korean National Institute of Health Services database spanning the years 2013 to 2019. The study accessed the AF incidence rate within 12 months in patients without a prior history of AF. Events occurring within 3 months of RI diagnosis were excluded to mitigate cases diagnosed during the initial screening or those with AF diagnoses that were potentially overlooked in the past. RESULTS: AF occurred in 19.1% of patients with RI over the entire period (median: 2.5 years, interquartile range 1.04-4.25 years). The majority of AF cases (16.1%) occured within the first year, resulting in an overall incidence rate of 7.0 per 100 person-years. Patients with newly developed AF were, on average, older than those who did not develop AF (64.1 vs. 57.3 years, P < 0.001). The independent predictors of AF were identified as age, male sex, higher body mass index, current smoking, ischemic heart disease, and heart failure. CONCLUSIONS: Physicians should consider the implementation of active rhythm monitoring for patients with RI to identify potential occurrence of subclinical AF, even if not initially diagnosed during the initial screening after RI diagnosis.
Assuntos
Fibrilação Atrial , Sistema de Registros , Humanos , Fibrilação Atrial/epidemiologia , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/complicações , Masculino , Feminino , Incidência , Estudos Retrospectivos , Pessoa de Meia-Idade , República da Coreia/epidemiologia , Idoso , Infarto/epidemiologia , Infarto/diagnóstico , Programas Nacionais de Saúde/estatística & dados numéricos , Estudos de Coortes , Nefropatias/epidemiologia , Nefropatias/diagnóstico , AdultoRESUMO
BACKGROUND/AIMS: We aimed to analyze the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) by the disease course of heart failure (HF). METHODS: We evaluated 227 patients with HF in a multi-center retrospective cohort that included those with left ventricular ejection fraction (LVEF) ≤ 40% undergoing ARNI treatment. The patients were divided into patients with newly diagnosed HF with ARNI treatment initiated within 6 months of diagnosis (de novo HF group) and those who were diagnosed or admitted for HF exacerbation for more than 6 months prior to initiation of ARNI treatment (prior HF group). The primary outcome was a composite of cardiovascular death and worsening HF, including hospitalization or an emergency visit for HF aggravation within 12 months. RESULTS: No significant differences in baseline characteristics were reported between the de novo and prior HF groups. The prior HF group was significantly associated with a higher primary outcome (23.9 vs. 9.4%) than the de novo HF group (adjusted hazard ratio 2.52, 95% confidence interval 1.06-5.96, p = 0.036), although on a higher initial dose. The de novo HF group showed better LVEF improvement after 1 year (12.0% vs 7.4%, p = 0.010). Further, the discontinuation rate of diuretics after 1 year was numerically higher in the de novo group than the prior HF group (34.4 vs 18.5%, p = 0.064). CONCLUSION: The de novo HF group had a lower risk of the primary composite outcome than the prior HF group in patients with reduced ejection fraction who were treated with ARNI.
Assuntos
Insuficiência Cardíaca , Neprilisina , Humanos , Volume Sistólico , Estudos Retrospectivos , Função Ventricular Esquerda , Resultado do Tratamento , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/tratamento farmacológico , Anti-Hipertensivos , AntiviraisRESUMO
Few studies have compared the ability of sodium bicarbonate plus N-acetylcysteine (NAC) and sodium chloride plus NAC to prevent contrast-induced nephropathy (CIN) in diabetic patients with impaired renal function undergoing coronary or endovascular angiography or intervention. Diabetic patients (n = 382) with renal disease (serum creatinine ≥1.1 mg/dl and estimated glomerular filtration rate <60 ml/min/1.73 m(2)) were randomly assigned to receive prophylactic sodium chloride (saline group, n = 189) or sodium bicarbonate (bicarbonate group, n = 193) before elective coronary or endovascular angiography or intervention. All patients received oral NAC 1,200 mg 2 times/day for 2 days. The primary end point was CIN, defined as an increase in serum creatinine >25% or an absolute increase in serum creatinine ≥0.5 mg/dl within 48 hours after contrast exposure. There were no significant between-group differences in baseline characteristics. The primary end point was met in 10 patients (5.3%) in the saline group and 17 (9.0%) in the bicarbonate group (p = 0.17), with 2 (1.1%) and 4 (2.1%), respectively, requiring hemodialysis (p = 0.69). Rates of death, myocardial infarction, and stroke did not differ significantly at 1 month and 6 months after contrast exposure. In conclusion, hydration with sodium bicarbonate is not superior to hydration with sodium chloride in preventing CIN in patients with diabetic nephropathy undergoing coronary or endovascular angiography or intervention.
Assuntos
Acetilcisteína/administração & dosagem , Angioplastia Coronária com Balão/efeitos adversos , Meios de Contraste/efeitos adversos , Angiografia Coronária/efeitos adversos , Nefropatias Diabéticas/complicações , Insuficiência Renal/prevenção & controle , Bicarbonato de Sódio/administração & dosagem , Cloreto de Sódio/administração & dosagem , Administração Oral , Idoso , Creatinina/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Renal/induzido quimicamenteRESUMO
We describe a 72-year-old man who presented with left hemiparesis due to acute cerebral infarction in the right fronto-temporal lobe. Three months prior to admission, he was hospitalized for right hemiparesis due to the acute cerebral infarction in the left anterior cerebral artery territory. To investigate the cause of his recurrent embolic event, a chest computed tomography scan and echocardiography were performed, which revealed advanced lung cancer invading contiguously through the pulmonary veins to the right main pulmonary artery and left atrium. Tumor embolism is a rare cause of stroke, occurring with primary or metastatic neoplasms of the lung. Echocardiography is a useful tool in patients with cerebral embolic episodes.
Assuntos
Reestenose Coronária/prevenção & controle , Diabetes Mellitus/fisiopatologia , Stents Farmacológicos , Paclitaxel/uso terapêutico , Sirolimo/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Reestenose Coronária/etiologia , Reestenose Coronária/mortalidade , Humanos , Imunossupressores/uso terapêutico , Fatores de Risco , Fatores de Tempo , Resultado do TratamentoRESUMO
Several techniques are available for measuring platelet function during aspirin therapy, but none is well standardized, and the reported incidence of aspirin non-responders varies widely, from 5 to 50%. We evaluated the optical platelet aggregation test and the Platelet Function Analyzer-100 test (PFA-100) for assessing aspirin responsiveness in patients receiving dual anti-platelet therapy, and we measured the incidence of non-responders to aspirin among Koreans. The study enrolled 88 participants including 51 patients on dual anti-platelet therapy, 31 controls, and 6 other volunteers. Optical platelet aggregation in response to 4 agonists and aggregation using the PFA-100 test were determined. In addition, medical records, including the results of platelet aggregation tests, were reviewed for 351 patients receiving aspirin therapy. The results showed good correlation between the PFA-100 test using a collagen/epinephrine cartridge (CEPI) and the optical platelet aggregation test using each agonist. The platelet aggregation test using arachidonic acid revealed marked suppression of aggregation (>98% inhibition) in patients taking aspirin; this value was highly correlated with the PFA-100 results using the CEPI cartridge. Seven of 351 Korean subjects (2.0%) receiving aspirin treatment were non-responsive to aspirin. This study shows that the optical platelet aggregation test using arachidonic acid gave an accurate assessment of the response to aspirin, and that results of the PFA-100 test using the CEPI cartridge correlated well with results of the optical platelet aggregation test.